참고문헌
- Abd El-Rehim DM, Ball G, Pinder SE, et al (2005). High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer, 116, 340-50. https://doi.org/10.1002/ijc.21004
- Bhargava V, Kell DL, Rijn M, et al (1994). Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol, 145, 535-40.
- Bilalovic N, Vranic S, Hasanagic S, et al (2004). The Bcl-2 protein: a prognostic indicator strongly elated to ER and PR in breast cancer. Bosn J Basic Med Sci, 4, 5-12.
- Callagy G, Cattaneo E, Daigo Y, et al (2003). Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol, 12, 27-34. https://doi.org/10.1097/00019606-200303000-00004
- Callagy GM, Pharoah PD, Pinder SE, et al (2006). Bcl-2 is a prognostic marker in breast cancer independently of the nottingham prognostic index. Clin Cancer Res, 12, 2468-75. https://doi.org/10.1158/1078-0432.CCR-05-2719
- Cecka F, Hornychova H, Melichar B, et al (2008). Expression of bcl-2 in breast cancer: correlation with clinicopathological characteristics and survival. Acta Medica(Hradec Kralove), 51, 107-12.
- Dawson SJ, Makretsov N, Blows FM, et al (2010). BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer, 103, 668-75. https://doi.org/10.1038/sj.bjc.6605736
- De Giorgi U, Rosti G, Frassineti L, et al (2007). High-dose chemotherapy for triple negative breast cancer. Ann Oncol, 18, 202-3.
- de Ruijter TC, Veeck J, de Hoon JPJ, et al (2011). Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol,137, 183-92. https://doi.org/10.1007/s00432-010-0957-x
- dos Santos LG, Lopes-Costa PV, dos Santos AR, et al (2008). Bcl-2 oncogene expression in estrogen receptor-positive and negative breast carcinoma. Eur J Gynaecol Oncol, 29, 459-61.
- Ismail-Khan R, Bui MM (2010). A review of triple-negative breast cancer. Cancer Control, 17, 173-6.
- Jemal A, Siegel R, Ward E, et al (2007). Cancer statistics. CA Cancer J Clin, 57, 43-66. https://doi.org/10.3322/canjclin.57.1.43
- Kallel-Bayoudh I, Hassen HB, Khabir A, et al (2011). Bcl-2 expression and triple negative profile in breast carcinoma. Med Oncol, 28, 55-61. https://doi.org/10.1007/s12032-010-9694-x
- Kaplan HG, Malmgren JA, Atwood MK (2006). Impact of triple negative phenotype on breast cancer prognosis. Poster presented at: 29th Annual San Antonio Breast Cancer Symposium; December 14-17, San Antonio, TX.
- Kreike B, van Kouwenhove M, Horlings H, et al (2007). Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res, 9, 65. (doi:10.1186/bcr1771)
- Kumar R, Vadlamudi RK, Adam L. (2000). Apoptosis in mammary gland and cancer. Endocr Relat Cancer, 7, 257-69. https://doi.org/10.1677/erc.0.0070257
- Lipponen P, Pietilainen T, Kosma VM et al (1995). Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J Pathol, 177, 49-55. https://doi.org/10.1002/path.1711770109
- Mathieu MC, Rouzier R, Llombart-Cussac A et al (2004). The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer,40, 342-51.
- Mimori K, Kataoka A, Yoshinaga K et al (2005). Identification of molecular markers for metastasis-related genes in primary breast cancer cells. Clin Exp Metastasis, 22, 59-67. https://doi.org/10.1007/s10585-005-4417-y
- Mottolese M, Benevolo M, Del Monte G et al(2000). Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy. J Cancer Res Clin Oncol, 126, 722-9. https://doi.org/10.1007/PL00008478
- Munster PM, Norton L.(2001). Predictive factor for the response to adjuvant therapy with emphasis in breast cancer. Breast Cancer Res, 3, 361-4. https://doi.org/10.1186/bcr323
- Nadler Y, Camp RL, Giltnane JM et al (2008). Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. Breast Cancer Res, 10, 35 (doi:10.1186/bcr1998)
- Neri A, Marrelli D, Roviello F et al (2006). Bcl-2 expression correlates with lymphovascular invasion and long-term prognosis in breast cancer. Breast Cancer Res Treat, 99, 77-83. https://doi.org/10.1007/s10549-006-9183-2
- Paik S, Tang G, Shak S et al (2006). Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol, 24, 3726-34. https://doi.org/10.1200/JCO.2005.04.7985
- Park SH, Kim H, Song BJ. (2002). Down regulation of bcl2 expression in invasive ductal carcinomas is both estrogen and progesterone-receptor dependent and associated with poor prognostic factors. Pathol Oncol Res, 8, 26-30. https://doi.org/10.1007/BF03033697
- Perou CM, Sorlie T, Eisen MB et al (2000). Molecular portraits of human breast tumors. Nature, 406, 747-52. https://doi.org/10.1038/35021093
- Pinkas J, Martin SS, Leder P. (2004). Bcl-2-mediated cell survival promotes metastasis of EpH4 beta MEKDD mammary epithelial cells. Mol Cancer Res, 2, 551-6.
- Reed JC. (1994). Bcl-2 and the regulation of programmed cell death. J Cell Biol, 124, 1-6. https://doi.org/10.1083/jcb.124.1.1
- Reed JC, Miyashita T, Takayama S et al (1996). BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem, 60, 23-32. https://doi.org/10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.0.CO;2-5
- Sorlie T, Perou CM, Tibshirani R et al (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA, 98, 10869-74. https://doi.org/10.1073/pnas.191367098
- Sorlie T, Tibshirani R, Parker J et al (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA, 100, 8418-23. https://doi.org/10.1073/pnas.0932692100
- Subhawong AP, Nassar H, Halushka MK et al (2010). Heterogeneity of Bcl-2 expression in metastatic breast carcinoma. Mod Pathol, 23,1089-96. https://doi.org/10.1038/modpathol.2010.93
- Tavassoli FA, Devilee P (2003). World health organization of tumors. Pathology and genetics of tumors of the breast and female genital organs. Lyon, IARC press.
- Tawfik O, Davis K, Kimler BF, et al (2010). Clinicopathological characteristics of triple-negative invasive mammary carcinomas in African-American versus Caucasian women. Ann Clin Lab Sci, 40, 315-23.
- Thomadaki H, Talieri M, Scorilas A (2007). Prognostic value of the apoptosis related genes BCL2 and BCL2L12 in breast cancer. Cancer Lett, 247, 48-55. https://doi.org/10.1016/j.canlet.2006.03.016
- Trere D, Montanaro L, Ceccarelli C, et al (2007). Prognostic relevance of a novel semiquantitative classification of Bcl2 immunohistochemical expression in human infiltrating ductal carcinomas of the breast. Ann Oncol, 18, 1004-14. https://doi.org/10.1093/annonc/mdm074
- Tsujimoto Y, Croce CM (1986). Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA, 83, 5214-8. https://doi.org/10.1073/pnas.83.14.5214
- Van't Veer LJ, Dai H, van de Vijver MJ, et al (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415, 530-6. https://doi.org/10.1038/415530a
- Zinkel S, Gross A, Yang E (2006). BCL2 family in DNA damage and cell cycle control. Cell Death Differ, 13, 1351-9. https://doi.org/10.1038/sj.cdd.4401987
피인용 문헌
- Expression of Cox-2 and Bcl-2 in Paget's Disease of the Breast vol.16, pp.3, 2015, https://doi.org/10.7314/APJCP.2015.16.3.1041
- Bcl-2 antigen expression in luminal A and triple-negative breast cancer vol.34, pp.9, 2017, https://doi.org/10.1007/s12032-017-1022-2
- Bcl-2 expression and prognostic significance in feline invasive mammary carcinomas: a retrospective observational study vol.15, pp.1, 2019, https://doi.org/10.1186/s12917-018-1772-x